RESEARCH ARTICLE SERUM SYNDECAN-1 AND APOLIPOPROTEIN A1 IN PATIENTS WITH CHRONIC HCV INFECTION

Document Type : Original Article

Authors

1 Debartment of Biochemistry, Faculty of Medicine, Sohag University.

2 Departments of Medical Biochemistry, Faculty of Medicine, Sohag University.

3 Departments of Medical Biochemistry, Faculty of Medicine, Assuit University.

4 Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University.

Abstract

Hepatitis C virus (HCV) is endemic in Egypt. Over 15% of populations of the people in Egypt are infected, this is ten times greater than in any other country in the world. To validate a simple, inexpensive, non invasive markers (Fib-4, APRI, syndecan-1 and apolipoprotein A-1(ApoA-1) for detection of liver fibrosis in patients with chronic HCV and thereby reduce the need for liver biopsy. Estimation of serum syndecan-1 and apoA-1 by ELISA were done on 20 normal healthy persons and 57 chronic hepatitis C patients, the patients were staged according to liver biopsies (Metavir fibrosis staging) (stage f1=15, f2=15, f3=14,f4= 13). The area under the receiver operating characteristic (ROC) curve (AUC) of syndecan-1=(0.72), the mean level of plasma syndecan-1 was significantly higher in chronic HCV patients when compared to control subjects (P=0.0008), but the mean level of ApoA-1 was not significantly different from that of controls (p=o.65), and it had significant negative correlation to the stage of fibrosis (AUC=0.57). Moreover the APRI and Fib-4 were proved significantly directly correlated with fibrosis stage of the studied patients. This study not reveals putative biomarkers of liver fibrosis (syndecan-1, ApoA-1 APRI, Fib-4) but also proves the differential expression of those markers in different stages of fibrosis. It is expected that combination of these novel biomarkers could be applied clinically to predict the stage of liver fibrosis without the need of liver biopsy.

 
Copyright © 2015 Nagwa S. Ahmed et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords

Main Subjects

References

  1. Afdhal, NH. and Nunes, D. 2004. Evaluation of liver fibrosis: a concise review. Am J Gastro- enterol.; 99(6):1160–1174.
  2. Anttonen A, Leppä S, Ruotsalainen T, Alfthan H, Mattson K, Joensuu H. 2003. Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 41:171–7.
  3. Bedossa, P. and Poynard, T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24 (2):289–93.
  4. Bedossa, P., Dargere, D. and Paradis V. 2003. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology, 38(6): 1449–1457
  5. Bedossa, P., Poynard T., Abella A., Paraf F., Lemaigre, G and Martin, ED. 1989. Localization of apolipoprotein A-I and apolipoprotein A-II in normal and atherosclerotic arteries. Arch Pathol Lab Med., 113:777-780.
  6. Calès      P1., Oberti      F., Michalak      S., Hubert-Fouchard I., Rousselet    MC., Konaté    A., Gallois    Y., Ternisien C., Chevailler A. and Lunel F. 2005. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology, 42:1373-1381.
  7. Chen SL. and Morgan TR. 2006. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci., 3 : 47-52. Dudas J., Kovalszky I., Gallai M., Nagy J.O, Schaff Z., Knittel T., Mehde M., Neubauer K., Szalay F. and Ramadori G.
  8. 2001. Expression of decorin, transforming growth factor- beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis, Am J Clin Pathol., 115, 725–735.
  9. Forns   X., Ampurdanès   S., Llovet    JM., Aponte    J.,  Quintó L., Martínez-Bauer E., Bruguera M., Sánchez- Tapias JM. and Rodés J. 2002. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 36:986-992.
  10. Friedman LS. 2004. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep., 6(1): 30–36.
  11. Friedman  SL.  2008. Mechanism of hepatic fibrogenesis.
  12. Gastroenterology, 134:1655–69.
  13. Gangadharan B., Antrobus R., Dwek RA. and Zitzmann N 2007. Novel Serum Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients. Clinical Chemistry, 53:1792–1799.
  14. Gressner A.M., Krull N. and. Bachem M.G. 1994. Regulation of proteoglycan expression in fibrotic liver and cultured fat-storing cells. Pathol Res Pract., 190, 864–882
  15. Gressner AM. 1998. The cell biology of liver fibrogenesis an imbalance of proliferation growth arrest and apoptosis of myofibroblasts. Cell Tissue Res., 292:447-52.
  16. Heinegard D. and Oldberg A. 1989. Structure and biology of cartilage and bone matrix noncollagenous macromolecules, FASEB J3, 2042–2051.
  17. Hogemann B., Edel G., Schwarz K., Krech R. and Kresse H. 1997. Expression of biglycan, decorin and proteoglycan- 100/CSF-1 in normal and fibrotic human liver, Pathol Res Pract193, 747–751.
  18. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y. and Poynard T. 2001. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, 357:1069-1075.
  19. Jarnagin W.R., Rockey D.C., Koteliansky V.E., Wang S.S and. Bissell D.M. 1994. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis, J Cell Biol., 127 :2037–2048.
  20. Kainulainen V., Wang H., Schick C. and Bernfield M. 1998. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem., 273: 11563–9.
  21. Kim CW., Goldberger OA., Gallo RL. and Bernfield, M. 1994. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue- and development-specific patterns. Mol Biol Cell., 5: 797–805.
  22. Kim  TH., Lee  YH., Kim  KH., Lee   SH., Cha   JY., Shin EK., Jung S., Jang AS., Park SW., Uh ST., Kim YH., Park JS., Sin   HG., Youm   W., Koh   ES., Cho    SY., Paik  YK., Rhim TY. and Park CS. 2010. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med., 182: 633–642.
  23. Le  Calvez  S., Thabut  D., Messous  D., Munteanu   M., Ratziu V., Imbert-Bismut F. and Poynard, T. 2004. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C., Hepatol; 39:862-3.
  24. Lee EH., Lee EJ., Kim HJ., Jang AS., Koh ES., Kim Y., Park,
  25. S. and Park, C. 2013. Overexpression of Apolipoprotein  A1 in the Lung Abrogates Fibrosis in Experimental Silicosis. PLoS ONE 8(2): e55827.
  26. Li Q., Park PW., Wilson CL. and Parks WC. 2002. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell, 111:635.
  27. Martı´nez S M., Crespo G., Navasa M. and Forns X. 2011. Noninvasive Assessment of Liver Fibrosis: Hepatology, 53:325-335
  28. Martinez-Hernandez and Amenta P.S. 1993. The hepatic extracellular matrix. I. Components and distribution in normal liver, Virchows Arch A Pathol Anat Histopatho. l423, 1–11.
  29. Miller GJ. 1980. High density lipoproteins and atherosclerosis.
  30. Annu Rev Med., 31:97-108.
  31. Myers   RP., Benhamou    Y., Imbert-Bismut    F., Thibault   V., Bochet      M., Charlotte      F., Ratziu      V., Bricaire F., Katlama C. and Poynard T. 2003. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS; 17:721–5.
  32. Naveau S., Poynard T., Benattar C., Bedossa P. and Chaput  JC. 1994. Alpha-2-macroglobulin and hepatic fibrosis: diagnostic interest. Dig Dis Sci., 1994; 39:2426–32.
  33. Paradis  V1., Laurent  A., Mathurin  P., Poynard  T., Vidaud D., Vidaud M. and Bedossa P. 1996. Role of liver extracellular matrix in transcriptional and post-transcriptional regulation of apolipoprotein A-I by hepatocytes. Cell Mol Biol., 42:525–34.
  34. Parkes J., Guha IN., Roderick P. and Rosenberg W. 2006. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol., 44(3):462–474.
  35. Parsian H., Alizadeh M. and Negahdar H. 2012. Would the Physicians Eventually Obsolete the Liver Biopsy for the Assessment of Liver  Fibrosis?  Hepat  Mon.,  12(5):  353-4. DOI: 10.5812/hepatmon.6227.
  36. Pichard A.V., Mallet V., Nalpas B., Verkarre V., Nalpas A., Venier VD., Fontaine H. and Pol S. 2007. FIB-4: an Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison with Liver Biopsy and FibroTest. HEPATOLOGY, 46, (1), 32-36.
  37. Poynard T., Abella A., Pignon JP., Naveau S., Leluc R. and Chaput, JC. 1987. Apolipoprotein A-I and alcoholic liver disease. HEPATOLOGY;6:1391-1395.
  38. Poynard   T., Aubert   A., Bedossa   P., Abella    A., Naveau  S., Paraf F. and Chaput JC. 1991. A simple biological  index for detection of alcoholic liver disease in drinkers. Gastroenterology; 100:1397–402.
  39. Regev A., Berho  M., Jeffers  LJ., Milikowski  C., Molina  EG., Pyrsopoulos NT., Feng ZZ., Reddy KR. and Schiff ER. 2002. Sampling error and interobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol., 97: 2614-2618.
  40. Rosenberg  WM1., Voelker  M., Thiel  R., Becka   M., Burt  A., Schuppan D., Hubscher S., Roskams T., Pinzani  M. and Arthur MJ. 2004. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology, 127:1704- 1713.
  41. Ryan KJ., Ray C.G. (editors), ed. 2004. Sherris Medical Microbiology  (4th  ed.).  McGraw   Hill.   pp. 551–.   ISBN 0838585299. 2- Rossi EG, Cardoso LF, Ávila WS, et al. Estenose Mitral em assintomáticos. Rev Soc Cardiol Estado de São Paulo 1997;7:741–746.
  42. Sabile  A1, Perlemuter  G., Bono  F., Kohara  K., Demaugre F., Kohara M., Matsuura  Y., Miyamura  T., Bréchot  C. and Barba, G. 1999. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology; 30:1064–76.
  43. Seidel    C., Sundan    A., Hjorth    M., Turesson     I., Dahl IM., Abildgaard N., Waage A. and Borset M. 2000. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood;95: 388–92
  44. Shah AG., Lydecker A., Murray K., Tetri BN., Contos MJ. and Sanyal AJ. 2009. (Nash Clinical Research Network. Comparison of noninvasive markers of  fibrosis  in  patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. Oct; 7(10): 1104-12.
  45. Snyder N., Gajula L., Xiao  SY., Grady  J., Luxon  B., Lau DT., Soloway R. and Petersen J. 2006. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis
  46. C. J Clin Gastroenterol., 40(6):535-42.
  47. Stepp MA., Liu Y., Pal-Ghosh S., Jurjus RA., Tadvalkar G., Sekaran A., Losicco K., Jiang L., Larsen M., Li L. and Yuspa SH. 2007. Reduced migration, altered matrix and enhanced TGFbeta1 signaling are signatures of mouse keratinocytes lacking Sdc1. J Cell Sci., 120:2851–2863.
  48. Sterling   RK., Lissen   E., Clumeck   N., Sola   R., Correa MC., Montaner J., S Sulkowski M., Torriani FJ., Dieterich DT., Thomas DL., Messinger D. and Nelson M. 2006. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 43(6):1317-1325.
  49. Subramanian SV., Fitzgerald ML. and Bernfield M. 1997. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem., 272: 14713–20.
  50. Teare  JP., Sherman  D., Greenfield  SM., Simpson  J., Bray G., Catterall AP., Murray-Lyon IM., Peters TJ., Williams
  51. R. and Thompson RP. 1993. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet; 342:895–98.Thampanitchawong P. and Piratvisuth T 1999. Liver biopsy:complications and risk factors. World J Gastroenterol, 5:301-304.
  52. Thomas DL1, Astemborski J., Rai RM., Anania FA., Schaeffer M., Galai N., Nolt K., Nelson KE., Strathdee SA., Johnson L., Laeyendecker O., Boitnott J., Wilson LE. and Vlahov
  53. D. 2000. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama 284: 450–456.
  54. Vozar I. 2005. Serum laboratory markers for non invasive diagnosis and monitoring of liver fibrogenesis in patients with chronic liver diseases. Bratisl Lek Listy;106(3) :123- 6.
  55. Wai      CT1, Greenson      JK., Fontana      RJ., Kalbfleisch JD., Marrero JA., Conjeevaram HS. and Lok AS. 2003. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 38: 518-26.
  56. World Health Organisation 2012, mediacentre/factsheets/ fs164/en/. Available : http://www.who.int/ May 23.
  57. Yang H R., Kim H R., Kim M J., Ko J S. and Seo J K. 2012. Noninvasive Parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastro‐enteric, l7; 18(13): 1525–30.
  58. Zannis VI., Kypreos KE., Chroni A., Kardassis D, Zanni EE. 2004. Lipoproteins and atherogenesis. In: Molecular Mechanisms of Atherosclerosis.Loscalzo J (ed). Taylor & Francis, New York, NY, pp. 111–74.

 

 

Sohag Medical Journal
Volume 23, Issue 2
April 2019
Pages 204-218

Files

Share

How to cite

Statistics